RenovoRx, Inc. (RNXT)
1.15
-0.04
(-3.36%)
USD |
NASDAQ |
Nov 06, 16:00
1.15
0.00 (0.00%)
After-Hours: 16:56
RenovoRx Research and Development Expense (Annual) : 6.269M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 6.269M |
| December 31, 2024 | 6.025M |
| December 31, 2023 | 5.667M |
| December 31, 2022 | 4.301M |
| Date | Value |
|---|---|
| December 31, 2021 | 3.039M |
| December 31, 2020 | 2.386M |
| December 31, 2019 | 2.997M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Enanta Pharmaceuticals, Inc. | 106.74M |
| Travere Therapeutics, Inc. | 206.01M |
| REGENXBIO, Inc. | 212.68M |
| Krystal Biotech, Inc. | 52.32M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |